- Biotech company Recursion buys Exscientia for $688 millionReuters
- AI-powered pharmaceutical research company Exscientia to merge with Nvidia partner Recursion PharmaceuticalsYahoo Finance
- Recursion’s Acquisition of Exscientia Makes Sense on Some Levels, But Not Others (NASDAQ:EXAI)Looking for Alpha
- AI drug developers Recursion and Exscientia to mergeSTAT
- After a tough year, Exscientia integrates with Recursion to create an AI superpowerFierce Biotechnology
